Abstract: The present invention concerns s-SHIP promoter and developmental decision promoter compositions and methods of using the promoter. It includes polynucleotides, vectors, host cells, and transgenic animal including a developmental decision promoter, for example, an s-SHIP promoter, controlling the expression of a heterologous nucleic acid. Methods of the invention concern methods of expressing a heterologous nucleic acid is a tissue-specific, developmental-specific, or temporally controlled manner. Other methods includes screening methods and therapeutic methods.

Abstract: The present invention relates to newly identified human polynucleotides and the polypeptides encoded by these polynucleotides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human antigens. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human antigens.

Abstract: Glucosidase I inhibitors as therapeutic agents for combatting nondefective retroviral pathogens, including the aetiological agents of AIDS and feline leukemia. Administration of a processing glucosidase I inhibitor, preferably castanospermine, interrupts the replication of the retrovirus in infected cells, alleviates pathogenic effects associated with the presentation of vital env glycoproteins on infected cells, and may furthermore prevent infection of target cells by interrupting expression of endogenous receptors recognized by the virion.

Abstract: Glucosidase I inhibitors as therapeutic agents for combatting nondefective retroviral pathogens, including the aetiological agents of AIDS and feline leukemia. Administration of a processing glucosidase I inhibitor, preferably castanospermine, interrupts the replication of the retrovirus in infected cells, alleviates pathogenic effects associated with the presentation of viral env glycoproteins on infected cells, and may furthermore prevent infection of target cells by interrupting expression of endogenous receptors recognized by the virion.

Abstract: A method of regulating oncogene-mediated cell transformation in a mammalian host. Oncogenes having glycosylated expression products are regulated by administering an effective amount of a processing glucosidase inhibitor: a glucosidase I inhibitor, e.g., castanospermine, N-methyl-1-deoxynojirimycin, 1-deoxynojirimycin, 5-amino-5-deoxy-D-glucopyranose; or a glucosidase II inhibitor, e.g., bromoconduritol. The glucosidase I inhibitors are preferred, particularly castanospermine (CA) and N-methyl-1-deoxynojirimycin (MdN). Oncogenes having glycosylated expression products that are ultimately expressed on the plasma membrane or secreted from transformed cells are particularly susceptible to regulation by these anti-cancer drugs. Also provided is a method of regulating the immune system of a mammalian host. Administration of an effective amount of a processing glucosidase inhibitor suppresses proliferation and differentiation of monocytic and myeloblastic cells.